Vor Biopharma Inc. (NYSE:VOR) Receives $8.86 Consensus Target Price from Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned an average rating of "Buy" from the seven research firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.86.

A number of brokerages have commented on VOR. Wedbush reiterated an "outperform" rating and issued a $7.00 target price on shares of Vor Biopharma in a report on Thursday, March 20th. Oppenheimer reiterated an "outperform" rating and issued a $8.00 price target on shares of Vor Biopharma in a report on Friday, March 21st. HC Wainwright reduced their price objective on Vor Biopharma from $17.50 to $13.00 and set a "buy" rating for the company in a research note on Friday, March 21st. JMP Securities restated a "market outperform" rating and set a $12.00 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus dropped their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 21st.

Vor Biopharma Price Performance

Shares of NYSE VOR traded down $0.01 during midday trading on Thursday, reaching $0.75. 157,095 shares of the stock traded hands, compared to its average volume of 590,688. The stock has a market capitalization of $51.70 million, a PE ratio of -0.46 and a beta of -0.40. The company's 50 day moving average is $1.16 and its 200 day moving average is $1.01. Vor Biopharma has a one year low of $0.63 and a one year high of $2.43.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VOR. Two Sigma Investments LP grew its position in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares during the last quarter. Northern Trust Corp increased its position in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma in the 4th quarter valued at $102,000. RA Capital Management L.P. lifted its stake in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Vor Biopharma in the 4th quarter worth approximately $80,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.